Likewise, tumor-bearing mice also expressed higher levels of cell surface CTLA-4 than naïve mice, allowing us to reveal downregulation of CTLA-4 by Ipilimumab in the absence of anti-PD-1 treatment (Supplementary Information, Fig. S1f, g). The gene discussed is CTLA4; the disease is neoplasm.